威尼斯在线平台-澳门威尼斯网站登录

?
北京、成都等六地区74 家医院2013 年调脂药使用分析
在线阅读 >
x

请在关注微信后,向客服人员索取文件

篇名: 北京、成都等六地区74 家医院2013 年调脂药使用分析
TITLE:
摘要:

目的:为调脂药的采购供应和临床合理使用提供参考。方法:对北京、成都、广州、杭州、上海、天津六地区74 家医院2013

年159 506 例患者进行流行病学调查,统计并分析调脂药的销售金额、用药频度、日均费用(DDC)、实际日均剂量及排序比。结

果:综合各地区,高脂血症患病率较高,为29.56%,呈地域性分布和年轻化趋势,伴有高血压、糖尿病及冠心病的患者患病率更

高。阿托伐他汀使用量最大,但DDC也较高;相比之下,瑞舒伐他汀更具有市场优势;辛伐他汀DDC较低,更适用于经济受限患

者。除北京、天津用药剂量较大外,其他地区多低于限定日剂量。结论:他汀类主导了调脂药市场,新型调脂药上市及联合用药为

治疗提供了新选择。

ABSTRACT:

OBJECTIVE:To provide reference for drug procurement and supply and rational use of lipid-regulating agents.

METHODS:The epidemiological investigation was carried out among 159 506 cases from 74 hospitals in Beijing,Chengdu,

Guangzhou,Hangzhou,Shanghai and Tianjin in 2013. The utilization of lipid-regulating agents was analyzed statistically in respects

of purchase value,DDDs,DDC,actual average daily dose and sort ratio. RESULTS:The prevalence rate of hyperlipidemia

was relatively high,accounting for 29.56% and showing a tendency of regional distribution and young age in all regions. The patients

with hypertension,diabetes and coronary heart disease had a higher incidence to suffer from hyperlipidemia. The use of atorvastatin

was in the first place,but it also had a higher DDC;while rosuvastatin hasd the advantage over aorvastatin in drug market.

Simvastatin had a lower DDC and was more suitable for the patients with low income. The doses of lipid-regulating agents in other

regions were lower than DDD except for those in Beijing and Tianjin. CONCLUSIONS:Statins dominate the lipid-regulating

agents market. But new lipid-regulating agents and drug combination provide a new choice for clinical treatment.

 

期刊: 2015年第26卷第35期
编辑: 孙秀波,张亚同,何祎晨,刘蕾
AUTHORS: SUN Xiu-bo,ZHANG Ya-tong,HE Yi-chen,LIU Lei1
关键字: 高脂血症;调脂药;流行病学调查;统计分析;北京;成都;广州;杭州;上海;天津
KEYWORDS: Hyperlipidemia;Lipid-regulating agents;Epidemiological investigation;Beijing;Chengdu;Guangzhou;Hangzhou;
阅读数: 111 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支撑与合作!

?